InsiderClue
Stocks · Health care · In Vitro & In Vivo Diagnostic Substances

Virax Biolabs Group Ltd

VRAX Clue Score27
United Kingdom Fiscal year ends March CIK 0001885827
$1.85 -1.07% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.85 +523.74% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 21 Jul 2022. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2021Revenue0.1Operating income−0.6Net income−0.7Fiscal year 2022Revenue0.0 −100.0%Operating income−1.7Net income−1.7EPS, diluted−1.79Fiscal year 2023Revenue0.0Operating income−5.7Net income−5.5EPS, diluted−5.13Fiscal year 2024Revenue0.2 +1,727.1%Operating income−6.5Net income−6.7EPS, diluted−3.36Fiscal year 2025Revenue0.0 −96.0%Operating income−6.2Net income−6.1EPS, diluted−1.62
FY2021FY2022FY2023FY2024FY2025
Revenue 0.1 0.0 0.0 0.2 0.0
Growth −100.0% +1,727.1% −96.0%
Operating income −0.6 −1.7 −5.7 −6.5 −6.2
Net income −0.7 −1.7 −5.5 −6.7 −6.1
Growth
EPS, diluted n/a −1.79 −5.13 −3.36 −1.62

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2021Gross margin−7.6%Operating margin−520.5%Net margin−525.8%Fiscal year 2022Fiscal year 2023Gross margin−15.9%Operating margin−66,963.7%Net margin−63,748.3%Fiscal year 2024Gross margin32.3%Operating margin−4,153.3%Net margin−4,304.8%Free cash flow margin−4,602.7%Fiscal year 2025Gross margin−838.2%Operating margin−97,344.8%Net margin−95,739.2%Free cash flow margin−81,621.6%
FY2021FY2022FY2023FY2024FY2025
Gross margin −7.6% n/a −15.9% 32.3% −838.2%
Operating margin −520.5% n/a −66,963.7% −4,153.3% −97,344.8%
Net margin −525.8% n/a −63,748.3% −4,304.8% −95,739.2%
Free cash flow margin n/a n/a n/a −4,602.7% −81,621.6%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2021Operating cash flow−0.6Fiscal year 2022Operating cash flow−0.8Fiscal year 2023Operating cash flow−4.2Fiscal year 2024Operating cash flow−6.2Capital expenditure−1.0Free cash flow−7.2Fiscal year 2025Operating cash flow−4.6Capital expenditure−0.6Free cash flow−5.2
FY2021FY2022FY2023FY2024FY2025
Operating cash flow −0.6 −0.8 −4.2 −6.2 −4.6
Capital expenditure n/a n/a n/a −1.0 −0.6
Free cash flow n/a n/a n/a −7.2 −5.2
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2021Cash0.0Shareholders’ equity−0.7Fiscal year 2022Cash0.0Shareholders’ equity−1.0Fiscal year 2023Cash9.4Shareholders’ equity9.1Fiscal year 2024Cash3.6Shareholders’ equity5.4Fiscal year 2025Cash4.2Shareholders’ equity5.7
FY2021FY2022FY2023FY2024FY2025
Cash 0.0 0.0 9.4 3.6 4.2
Shareholders’ equity −0.7 −1.0 9.1 5.4 5.7

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending March, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2021 31 Mar 2021 FY2022 31 Mar 2022 FY2023 31 Mar 2023 FY2024 31 Mar 2024 FY2025 31 Mar 2025
Margins
−7.6% n/a −15.9% 32.3% −838.2%
−520.5% n/a −66,963.7% −4,153.3% −97,344.8%
−543.5% n/a −63,751.5% −4,308.4% −97,992.3%
−525.8% n/a −63,748.3% −4,304.8% −95,739.2%
n/a n/a n/a −4,602.7% −81,621.6%
Spending
97.1% n/a 25,456.6% 998.6% 28,112.5%
369.6% n/a 41,491.1% 2,937.5% 68,394.1%
n/a n/a n/a 608.9% 9,538.6%
Returns
n/a n/a −59.8% −125.5% −106.4%
−1,643.0% −3,508.5% −55.6% −122.8% −94.3%
Balance and payout
2,199.4% 2,557.0% 9.3% 6.3% 15.0%